SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors debate the potential for a take-private bid by Trian Partners, fueling speculation of a massive short squeeze among a heavily shorted float. While some community members are bullish on the turnaround strategy and institutional backing, others are highlighting recent sales struggles and intense competition in the fast-food sector.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging as investors cheer a massive revenue beat and the company's ability to command premium pricing for its AI cloud infrastructure. The rally is being amplified by a potential short squeeze, with the community actively celebrating the stock's outperformance while aggressively calling out short sellers.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is facing intense criticism from investors frustrated by the company's declining share price and the perceived lack of progress on high-profile AI data center partnerships. Community sentiment remains deeply divided as shareholders express ongoing distrust toward management's leadership and compensation strategies ahead of the next quarterly earnings report.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as investors react to a blockbuster earnings report that featured massive revenue growth and a record backlog, fueling intense discussion about a potential short squeeze. While bulls are celebrating the guidance and strong order numbers, the community remains divided between those expecting a significant re-rating toward higher price levels and skeptics who are scrutinizing the sustainability of recent margin improvements.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is rallying as investors react to strong quarterly earnings, a significant revenue backlog, and management's raised guidance despite heavy capital expenditures. The market is actively debating the company's long-term debt profile against surging AI infrastructure demand, with many traders discussing a potential short squeeze as institutional confidence holds firm.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors focus on an upcoming Investor Day, where management is expected to provide critical updates on the NDA submission timeline for its wet AMD treatment, AXPAXLI. The community remains divided, with bullish participants betting on the potential of a best-in-class product and a possible buyout, while bears express skepticism over regulatory hurdles and the company's long-term commercial strategy.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is trending as investors brace for top-line Phase 2 data for its menopause drug, ABCL635, which the community views as a critical de-risking event for the company's antibody discovery platform. Despite ongoing debate regarding dilution and revenue performance, sentiment remains heavily focused on the clinical readout's potential to validate the company's long-term pipeline and shift market perception.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is surging following a strong quarterly report where the company significantly raised its AI infrastructure order outlook, signaling its pivotal role in the enterprise networking supercycle. Investors are reacting positively to the combination of impressive hyperscaler demand and a strategic workforce restructuring aimed at reallocating resources toward high-growth AI and security initiatives.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuum is generating significant buzz following its public debut, with community members closely tracking its high-profile partnership with Oracle to integrate its quantum technology into the Oracle Cloud. While some investors are bullish on its long-term potential and support from Honeywell, others are actively debating its high valuation and the risks associated with early-stage quantum firms.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is surging following positive Phase 3 topline results for its DT120 treatment in major depressive disorder, sparking intense community debate over its market valuation and long-term potential. While shareholders celebrate the clinical data and the company's strong cash position, active discussions are focused on comparing the stock against sector peers like Compass Pathways, evaluating the risks of upcoming share dilution, and debating whether the current momentum warrants a long-term hold or a tactical exit.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today

Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of $28.82 billion.read more...

What Insmed Stock's Premium Is Actually Buying

What Insmed Stock's Premium Is Actually Buying...

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.

Insmed Stock Jumps 33% Despite Narrower Q2 Loss

(RTTNews) - Insmed Incorporated (INSM) shares surged $32.83, or 33.16 percent, to $131.85 on Thursday, after the biopharmaceutical company reported a sharply narrower second-quarter loss, strong product revenue growth, and raised its full-year outlook for Brinsupri...

Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.read more...

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of +24.64% and +9.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update PR Newswire BRIDGEWATER, N.J., Aug. 6, 2026 Total Company Revenues of $425.5 Million for the Second Quarter of 2026BRINSUPRI...

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Baron Health Care Fund Remains Bullish on Insmed (INSM)

Here's Why Baron Health Care Fund Remains Bullish on?Insmed?(INSM...

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insmed Inc

INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study 

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

INSMInsmed Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest INSM News